Shares in Swiss pharmaceutical giant Roche jumped more than 3% in European trading today, after the company released positive late-stage trial results for a new cancer drug targeting non-small cell lung cancer. The data, presented at a medical conference overnight, showed the therapy met its primary endpoint of improving progression-free survival compared to standard care.
The rally lifted the broader healthcare sector across European markets. London-listed peers AstraZeneca and GSK both saw their shares rise by around 1% each, as investors bet on continued strength in oncology pipelines. The FTSE 100 was up 0.4% to 8,215 points by midday, with healthcare stocks among the top contributors.
Analysts at Jefferies described the data as “compelling” and noted that the treatment could become a standard-of-care option if regulatory approvals follow. “This de-risks a key part of Roche’s late-stage pipeline and reinforces the value of targeted therapies in oncology,” they said in a note to clients.
For UK investors with exposure to healthcare through pension funds or ETFs, the positive sentiment provides a tailwind for the sector, which has faced headwinds from patent expiries and pricing pressures in recent years. However, analysts caution that regulatory hurdles and manufacturing costs remain significant.
The development comes as the global oncology market continues to expand, with spending on cancer drugs projected to exceed £200bn annually by 2030. Roche’s success could also prompt increased merger and acquisition activity among mid-cap biotech firms, some of which are listed on London’s AIM market.